Publications
Research at the Leibniz Institute for Immunology focuses on the development of pioneering immune-cell therapies targeting cancer, autoimmune diseases, and chronic inflammation. While developments in this field are highly relevant within the medical community, they are also of great interest to the wider general public. The LIT has a comprehensive archive of international articles, publications, lectures, and online resources aimed at a variety of audiences. So, whoever you are, if you do not find what you are looking for, please do not hesitate to contact us.
Baldwin JG, Heuser-Loy C, Gattinoni L. Targeting organelle function in T cells for cancer immunotherapy. Nat Rev Immunol. 2025 Oct 9. doi:10.1038/s41577-025-01223-9. PMID: 41068297
Dragon AC, Thoelke S, Mausberg P, Zimmermann K, Blasczyk R, Hudecek M, Abken H, Schambach A, Maecker-Kolhoff B, Eiz-Vesper B. LMP2A-Targeting CAR-T Cells Equipped With Inducible IL-18 to Address EBV-Associated Malignancies. HLA. 2025 Oct. 106:e70439. doi:10.1111/tan.70439. PMID: 41116979
Buckley S, Miao Y, Idris M, Lee P-W, Scheller L, Riek R, Maerkl SJ, Abriata LA, Correia BE. 2025
De novo design of phosphorylation-induced protein switches for synthetic signaling in cells doi:10.1101/2025.09.10.675034.
Thomas S, Wermke M, Vucinic V, Wagner-Drouet E, Mackensen A, Zeiser R, Bug G, Schmitt M, Herr W, Prinz PU, Burdek M, Raffegerst S, Tafuri A, Geiger C, Crame K, Goedkoop R, Pinkernell K, Schendel DJ. First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms. Cancers (Basel). 2025 Sep 11. 17doi:10.3390/cancers17182968. PMID: 41008812
Piekarska A, Abouqateb M, Boreland W, Peczynski C, Zaucha JM, Kroger N, Zeiser R, Ciceri F, Schroeder T, Luft T, Passweg J, Kunadt D, Stelljes M, Blau IW, Platzbecker U, Yakoub-Agha I, Blaise D, Raiola AM, Tischer J, Wagner-Drouet EM, Winkler J, Schmid C, Wulf G, Edinger M, Maertens J et al. Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors – an EBMT registry study by the Transplant Complications Working Party. Bone Marrow Transplant. 2025 Sep 11. doi:10.1038/s41409-025-02692-1. PMID: 40931084
Nozari Z, Huttl P, Simeth J, Schon M, Hutchinson JA, Spang R. Harp: data harmonization for computational tissue deconvolution across diverse transcriptomics platforms. Bioinformatics. 2025 Sep 1. 41doi:10.1093/bioinformatics/btaf455. PMID: 40857392
Hansmann H, Henkel C, Fante MA, Harrer DC, Heidemanns S, Oellerich M, Beck J, Schutz E, Biswenger V, Perl M, Zartner B, Edinger M, Wolff D, Hoffmann P, Herr W, Banas B, Zecher D, Hansmann L. Sustained allogeneic kidney graft operational tolerance despite discontinued conventional immunosuppression after CD19-CAR-T cell therapy for relapsed/refractory posttransplant lymphoproliferative disorder. Am J Transplant. 2025 Sep 17. doi:10.1016/j.ajt.2025.09.009. PMID: 40972901
Teubner JP, Tumen D, Kandulski A, Heumann P, Mester P, Aschenbrenner E, Pollinger K, Gunckel M, Volz B, Hein T, Beltzig PL, Tengler L, Voll F, Kreutz M, Kunst C, Nicolay JP, Muller M, Gulow K. CRISPR-Cas9 screen reveals that inhibition of enhancer of zeste homolog 2 sensitizes malignant T cells to dimethyl-fumarate-induced cell death. FEBS J. 2025 Aug 1. doi:10.1111/febs.70208. PMID: 40748748
Perl M, Fante MA, Herfeld K, Scherer JN, Poeck H, Thiele Orberg E. Microbiota-derived metabolites: Key modulators of cancer immunotherapies. Med. 2025 Aug 8. 6:100773. doi:10.1016/j.medj.2025.100773. PMID: 40695291
Knoedler L, Herfeld K, Schaefer DA, Diatta F, Clune J, Evans B, Seu M, Kim BS, Alfertshofer M, Schaschinger T, Iske J, Knoedler S, Lellouch AG, Jeljeli M, Carturan A, Ruella M, Heiland M, Poeck H, Perl M, Pomahac B, Kauke-Navarro M. CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review. Cell Rep Med. 2025 Aug 19. 6:102240. doi:10.1016/j.xcrm.2025.102240. PMID: 40675157